Physician profile
Jason M Bart
NPI 1962594903
$3,003.12
in general payments reported to CMS, 2019-2025
12 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $80.38 · 2021: $371 · 2022: $360 · 2023: $658 · 2024: $573 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,326.23 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $271.83 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sight Sciences, INC. | $222.48 | 2019-2022 | |
| Biotissue Holdings INC. | $215.99 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $207.23 | 2023-2024 | Cequa |
| Bausch & Lomb Americas INC. | $193.99 | 2023-2024 | Miebo, Infuse, Biotrue One Day |
| Dompe US, INC. | $122.19 | 2025 | Oxervate |
| Glaukos Corporation | $117.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.07 | 2023 | Soliris |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.04 | 2019-2021 | |
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
| Allergan, INC. | $50.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.